1Y Close · As of Aug 26, 2026
Hanall Biopharma operates in the Pharmaceuticals sector.
Legal name: HANALL BIOPHARMA CO.,LTD
In fiscal year 2025, Hanall Biopharma (009420) reported revenue of 155.2 billion KRW, up 11.7% from 138.9 billion KRW a year earlier.
Operating profit was -916 million KRW and net income was -5.6 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 3.31 trillion KRW, with a P/B of 20.45.
These figures can be verified in the DART filing (receipt no. 20260318001637).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 155.2B | -916M | -5.6B |
| 2024 | 138.9B | 230M | -1.8B |
| 2023 | 134.9B | 2.2B | 3.5B |
Recent Filings
Semi-Annual Report (2026.06)
Corporate Briefing (IR) (Informational Disclosure)
Consolidated Operating (Preliminary) Earnings (Fair Disclosure)
Checks
No items require attention at this time.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: Treasury stock filings in the last 3 years: 6 disposal(s).
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-07-31 | Corporate Briefing (IR) (Informational Disclosure) |
| 2026-07-29 | Consolidated Operating (Preliminary) Earnings (Fair Disclosure) |